Thomas Olencki

10.8k total citations · 2 hit papers
122 papers, 4.0k citations indexed

About

Thomas Olencki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Thomas Olencki has authored 122 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Oncology, 53 papers in Pulmonary and Respiratory Medicine and 40 papers in Molecular Biology. Recurrent topics in Thomas Olencki's work include Cancer Immunotherapy and Biomarkers (32 papers), Renal cell carcinoma treatment (31 papers) and Immunotherapy and Immune Responses (18 papers). Thomas Olencki is often cited by papers focused on Cancer Immunotherapy and Biomarkers (32 papers), Renal cell carcinoma treatment (31 papers) and Immunotherapy and Immune Responses (18 papers). Thomas Olencki collaborates with scholars based in United States, Switzerland and Italy. Thomas Olencki's co-authors include Ronald M. Bukowski, Toni K. Choueiri, Donald P. Lawrence, Antoinette R. Tan, Ben L. Sanford, Eric J. Small, Jay A. Berzofsky, Daniel J. George, Geoffrey I. Shapiro and Susan Halabi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Thomas Olencki

120 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

2017 507 citations Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology profile →
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

2018 274 citations Saby George, Thomas Olencki et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Olencki United States	30	2.0k	1.8k	1.6k	886	797	122	4.0k
Hiroyuki Katoh Japan	34	1.8k 0.9×	1.5k 0.8×	1.4k 0.9×	937 1.1×	633 0.8×	163	4.6k
Erminia Massarelli United States	32	3.2k 1.6×	2.1k 1.2×	1.2k 0.8×	729 0.8×	648 0.8×	140	4.6k
Salvador Martín‐Algarra Spain	30	2.2k 1.1×	928 0.5×	1.3k 0.8×	1.1k 1.2×	722 0.9×	137	3.8k
Dimitrios Bafaloukos Greece	34	3.0k 1.5×	1.6k 0.9×	1.2k 0.8×	551 0.6×	867 1.1×	132	4.5k
Jens Atzpodien Germany	32	2.2k 1.1×	1.4k 0.8×	1.3k 0.8×	1.2k 1.4×	638 0.8×	141	3.9k
Julien Adam France	35	3.0k 1.5×	1.6k 0.9×	1.1k 0.7×	1.4k 1.6×	954 1.2×	171	4.7k
Peter Langmuir United States	30	1.8k 0.9×	1.6k 0.9×	1.3k 0.8×	888 1.0×	507 0.6×	56	4.7k
Takeshi Hanagiri Japan	35	1.8k 0.9×	1.8k 1.0×	1.2k 0.8×	1.0k 1.1×	448 0.6×	207	3.9k
Aurélie Cazes France	32	1.5k 0.7×	1.6k 0.9×	957 0.6×	627 0.7×	727 0.9×	108	3.8k
Chao Zhao China	34	2.3k 1.1×	2.0k 1.1×	1.1k 0.7×	479 0.5×	1.0k 1.3×	132	3.8k

Countries citing papers authored by Thomas Olencki

Since Specialization

Citations

This map shows the geographic impact of Thomas Olencki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Olencki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Olencki more than expected).

Fields of papers citing papers by Thomas Olencki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Olencki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Olencki. The network helps show where Thomas Olencki may publish in the future.

Co-authorship network of co-authors of Thomas Olencki

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Olencki. A scholar is included among the top collaborators of Thomas Olencki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Olencki. Thomas Olencki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Escudier, Bernard, Thomas Powles, Robert J. Motzer, et al.. (2018). Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology. 36(8). 765–772. 121 indexed citations

Abdel‐Rahman, Mohamed H., Leili Shahriyari, James B. Massengill, et al.. (2018). Identification of novel targeted therapies for BAP1 mutated tumors. Investigative Ophthalmology & Visual Science. 59(9). 4958–4958. 1 indexed citations

Choueiri, Toni K., Susan Halabi, Ben L. Sanford, et al.. (2017). Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology. 35(6). 591–597. 507 indexed citations breakdown →

Пили, Роберто, David I. Quinn, Hans J. Hammers, et al.. (2017). Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clinical Cancer Research. 23(23). 7199–7208. 76 indexed citations

Choueiri, Toni K., Colin Hessel, Susan Halabi, et al.. (2017). Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC). Annals of Oncology. 28. v623–v623. 12 indexed citations

Markowitz, Joseph, Jiang Wang, Jia You, et al.. (2017). Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Scientific Reports. 7(1). 15424–15424. 75 indexed citations

Markowitz, Joseph, Zachary B. Abrams, Naduparambil K. Jacob, et al.. (2016). MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. OncoTargets and Therapy. Volume 9. 5931–5941. 5 indexed citations

Lacouture, Mario E., John C. Morris, Donald P. Lawrence, et al.. (2015). Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunology Immunotherapy. 64(4). 437–446. 117 indexed citations

Olencki, Thomas. (2014). Optimal Treatment of Unresectable Nonmelanoma Skin Cancers. Journal of the National Comprehensive Cancer Network. 12(5S). 789–792. 1 indexed citations

10.

Abdel‐Rahman, Mohamed H., Colleen M. Cebulla, Benjamin Christopher, et al.. (2012). Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Experimental Eye Research. 100. 26–31. 37 indexed citations

11.

Borden, Ernest C., Barbara Jacobs, Lisa Rybicki, et al.. (2011). Gene Regulatory and Clinical Effects of Interferon β in Patients with Metastatic Melanoma: A Phase II Trial. Journal of Interferon & Cytokine Research. 31(5). 433–440. 25 indexed citations

12.

Kondadasula, Sri Vidya, et al.. (2008). The raf kinase inhibitor sorafenib inhibits Jak-STAT signal transduction in human immune cells. Cancer Research. 68. 1434–1434. 2 indexed citations

13.

Au, Jessie L.‐S., Thomas Olencki, M. Guillaume Wientjes, et al.. (2007). P2-230: A Phase I Study of Nontoxic Suramin As A Chemosensitizer In Pretreated/Refractory Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 2(8). S663–S664. 1 indexed citations

14.

Olencki, Thomas, L. Wood, Lisa Rybicki, et al.. (2007). Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon-α1b: A Second Member of the Interferon-α Family. Clinical Pharmacology & Therapeutics. 81(3). 354–361. 14 indexed citations

15.

Osborn, Blaire L., Mili Gu, Krzysztof Grzegorzewski, et al.. (2004). Preliminary pharmacokinetic evaluation of Albuleukin; an interleukin-2 human serum albumin fusion protein, in solid tumor patients. Cancer Research. 64. 1099–1099. 9 indexed citations

16.

Majhail, Navneet S., Mohamad A. Hussein, Thomas Olencki, et al.. (2004). Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer. Investigational New Drugs. 22(4). 421–426. 6 indexed citations

17.

Olencki, Thomas, et al.. (2002). A Phase I Trial of Weekly Gemcitabine and Subcutaneous Interferon Alpha in Patients with Refractory Renal Cell Carcinoma. Investigational New Drugs. 20(3). 305–310. 9 indexed citations

18.

Peereboom, D., Ram Ganapathi, Olaf van Tellingen, et al.. (1996). Phase I trial of vinblastine plus phenytoin Pharmacokinetic analysis. 37. 182. 1 indexed citations

19.

Olencki, Thomas, James H. Finke, R Tubbs, et al.. (1996). Immunomodulatory Effects of Interleukin-2 and Interleukin-4 in Patients with Malignancy. Journal of Immunotherapy. 19(1). 69–80. 5 indexed citations

20.

Wang, Qiu, Raymond Tubbs, Thomas Olencki, et al.. (1995). Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor‐infiltrating lymphocytes. International Journal of Cancer. 61(6). 780–785. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact